WALTHAM,
Mass., Dec. 14, 2023 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a
clinical-stage biopharmaceutical company developing an innovative
pipeline of cancer therapies, today announced that it plans to
offer and sell, subject to market and other conditions,
$150 million of shares of its common
stock in an underwritten public offering. Syndax also expects to
grant the underwriters a 30-day option to purchase up to an
additional 15% of the number of shares of common stock sold in the
public offering. All of the shares in the proposed offering are to
be sold by Syndax.
Goldman Sachs & Co. LLC, J.P. Morgan, TD Cowen and Stifel
are acting as joint book-running managers for the offering.
The shares are being offered pursuant to an automatically
effective "shelf" registration statement previously filed with the
Securities and Exchange Commission ("SEC"). A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the
website of the SEC at www.sec.gov. When available, copies of the
preliminary prospectus supplement and accompanying prospectus
relating to the offering may be obtained from: Goldman Sachs
and Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, NY 10282, telephone:
866-471-2526, facsimile: 212-902-9316 or by emailing
Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone:
(866) 803-9204, or by emailing prospectuseq_fi@jpmchase.com; Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; or
Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus
Department, One Montgomery Street,
Suite 3700, San Francisco,
California 94104, by telephone at (415) 364-2720 or by
emailing syndprospectus@stifel.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus, which are a part
of the effective registration statement.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective inhibitor of the menin–KMT2A binding interaction, and
axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance that Syndax
will be able to complete the proposed public offering on the
anticipated terms, or at all. Other factors that may cause Syndax's
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Syndax's filings with the SEC, including the "Risk Factors"
sections contained therein, as well as the risks identified in the
registration statement and the preliminary prospectus supplement
relating to the offering. These forward-looking statements are
based on Syndax's expectations and assumptions as of the date of
this press release. Except as required by law, Syndax assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-announces-proposed-150-million-public-offering-of-common-stock-302016108.html
SOURCE Syndax Pharmaceuticals, Inc.